Cancer care provider Helsinn's corporate venturing arm has invested in genomics diagnostics platform NovellusDx as part of a round that took its total funding to about $23m.
Israel-based genomics diagnostics technology developer NovellusDx has closed a $6m funding round featuring Helsinn Investment Fund, a vehicle sponsored by cancer care provider Helsinn Group.
The round also featured healthcare-focused venture capital firm Windham Venture Partners and investment fund Bio Capital Impact Fund.
Founded in 2011, NovellusDX has created a genomics analysis platform that provides data on mutations responsible for diseases such as cancer to help drug researchers develop enhanced treatments.
Proceeds from the round, which increased NovellusDx’s total funding to…
